| scholarly article | Q13442814 |
| P819 | ADS bibcode | 1981Sci...214.1239G |
| P356 | DOI | 10.1126/SCIENCE.6795720 |
| P698 | PubMed publication ID | 6795720 |
| P2093 | author name string | E J Schaefer | |
| G Ghiselli | |||
| P Gascon | |||
| H B Breser | |||
| P433 | issue | 4526 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1239-1241 | |
| P577 | publication date | 1981-12-01 | |
| P1433 | published in | Science | Q192864 |
| P1476 | title | Type III hyperlipoproteinemia associated with apolipoprotein E deficiency | |
| P478 | volume | 214 |
| Q35881442 | A 10-bp deletion in the apolipoprotein epsilon gene causing apolipoprotein E deficiency and severe type III hyperlipoproteinemia. |
| Q92192321 | A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward |
| Q24336518 | A plasma lipoprotein containing only apolipoprotein E and with gamma mobility on electrophoresis releases cholesterol from cells |
| Q34033587 | A pyrene based fluorescence approach to study conformation of apolipoprotein E3 in macrophage-generated nascent high density lipoprotein |
| Q68058495 | Abnormal lipoprotein and apolipoprotein pattern in lipoprotein glomerulopathy |
| Q35064519 | Acrolein modification impairs key functional features of rat apolipoprotein E: identification of modified sites by mass spectrometry |
| Q37288117 | Altered expression of genes functioning in lipid homeostasis is associated with lipid deposition in NOD mouse lacrimal gland |
| Q34308238 | Amelioration of nephropathy with apoA-1 mimetic peptide in apoE-deficient mice |
| Q92644885 | An experimental hyperlipidemia model with periodontitis in mice |
| Q64949177 | Analysis of apolipoprotein E genetic polymorphism in a large ethnic Hakka population in southern China. |
| Q43955453 | Anti-atherosclerotic effect of simvastatin depends on the presence of apolipoprotein E. |
| Q36991049 | ApoE deficiency exacerbates the development and sustainment of a semi-chronic K/BxN serum transfer-induced arthritis model |
| Q70126065 | ApoE deficiency: markedly decreased levels of cellular ApoE mRNA |
| Q36843340 | ApoE knockout and knockin mice: the history of their contribution to the understanding of atherogenesis |
| Q33746638 | Apolipoprotein E and atherosclerosis: insight from animal and human studies |
| Q57283531 | Apolipoprotein E deficiency accelerates atherosclerosis development in miniature pigs |
| Q35763533 | Apolipoprotein E deficiency in mice: gene replacement and prevention of atherosclerosis using adenovirus vectors |
| Q44503147 | Apolipoprotein E-4Philadelphia (Glu13—-Lys,Arg145—-Cys). Homozygosity for two rare point mutations in the apolipoprotein E gene combined with severe type III hyperlipoproteinemia |
| Q35577335 | Apolipoprotein E2-Christchurch (136 Arg----Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia |
| Q34497951 | Apolipoprotein E: From lipid transport to neurobiology |
| Q38751885 | Apolipoproteins in lipid transport, an impressionist view |
| Q35008817 | Assay methods of modified lipoproteins in plasma |
| Q33998681 | Astrocyte lipoproteins, effects of apoE on neuronal function, and role of apoE in amyloid-beta deposition in vivo |
| Q33821952 | Atypical familial dysbetalipoproteinemia associated with apolipoprotein phenotype E3/3. |
| Q43907946 | Bone marrow chimerism prevents atherosclerosis in arterial walls of mice deficient in apolipoprotein E. |
| Q34629472 | Characterization of high density lipoprotein binding to human adipocyte plasma membranes |
| Q39820316 | Classification of primary dyslipoproteinemias. |
| Q33837769 | Coherent somatic mutation in autoimmune disease |
| Q74057286 | Dietary fat clearance in type V hyperlipoproteinaemia secondary to a rare variant of human apolipoprotein E: the apolipoprotein E3 (Arg 136-->Ser) |
| Q92090764 | Differential Signaling Mediated by ApoE2, ApoE3, and ApoE4 in Human Neurons Parallels Alzheimer's Disease Risk |
| Q36326914 | Differential action of glucocorticoids on apolipoprotein E gene expression in macrophages and hepatocytes |
| Q67918863 | Effect of insulin, glucagon or dexamethasone on the production of apolipoprotein A-IV in cultured rat hepatocytes |
| Q43085965 | Effects of the absence of apolipoprotein e on lipoproteins, neurocognitive function, and retinal function |
| Q31798177 | Essential role for the (hepatic) LDL receptor in macrophage apolipoprotein E-induced reduction in serum cholesterol levels and atherosclerosis |
| Q24299817 | Familial apolipoprotein E deficiency |
| Q69951162 | Familial disorders of plasma apolipoproteins |
| Q40802354 | Familial lipoprotein disorders and premature coronary artery disease. |
| Q34204885 | Gene targeting approaches to complex genetic diseases: atherosclerosis and essential hypertension |
| Q37011453 | Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells |
| Q33847743 | Genetic basis of lipoprotein disorders |
| Q28306136 | Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels |
| Q36539906 | Human apolipoprotein E isoforms differentially affect bone mass and turnover in vivo |
| Q37370803 | Hypoxanthine induces cholesterol accumulation and incites atherosclerosis in apolipoprotein E-deficient mice and cells |
| Q34541650 | Immunoreactive apolipoprotein E is a widely distributed cellular protein. Immunohistochemical localization of apolipoprotein E in baboon tissues |
| Q64382653 | In the absence of endogenous mouse apolipoprotein E, apolipoprotein E*2(Arg-158 --> Cys) transgenic mice develop more severe hyperlipoproteinemia than apolipoprotein E*3-Leiden transgenic mice |
| Q36143345 | Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages |
| Q37016558 | Increased prevalence of apolipoprotein E4 in type V hyperlipoproteinemia |
| Q37743416 | Indications for lipid-lowering drugs |
| Q64116189 | Knockout rat models mimicking human atherosclerosis created by Cpf1-mediated gene targeting |
| Q33604083 | Lamellar lipoproteins uniquely contribute to hyperlipidemia in mice doubly deficient in apolipoprotein E and hepatic lipase |
| Q36682138 | Lipoprotein metabolism in nonalcoholic fatty liver disease |
| Q33822165 | Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic |
| Q37369657 | Liver-directed gene transfer and prolonged expression of three major human ApoE isoforms in ApoE-deficient mice |
| Q41919903 | Low and high density lipoprotein metabolism in primary cultures of hepatic cells from normal and apolipoprotein E knockout mice |
| Q36499963 | Low-dose expression of a human apolipoprotein E transgene in macrophages restores cholesterol efflux capacity of apolipoprotein E-deficient mouse plasma |
| Q39582081 | Macrophage-specific up-regulation of apolipoprotein E gene expression by STAT1 is achieved via long range genomic interactions. |
| Q34426934 | Metabolism of low-density lipoproteins by cultured hepatocytes from normal and homozygous familial hypercholesterolemic subjects |
| Q30238973 | Mouse models of atherosclerosis: a historical perspective and recent advances. |
| Q34616680 | New mutants of apolipoprotein E associated with atherosclerotic diseases but not to type III hyperlipoproteinemia |
| Q69126606 | Pharmacological treatment of lipid disorders in diabetes mellitus |
| Q72530926 | Phenotype study of apolipoprotein E isoforms in hyperlipoproteinaemic patients |
| Q52041566 | Preliminary report of a genetic basis for cognitive decline after cardiac operations. The Neurologic Outcome Research Group of the Duke Heart Center. |
| Q38023858 | Proinflammatory effects of C-Peptide in different tissues |
| Q34667425 | Proteomic identification of biomarkers of vascular injury. |
| Q71371377 | Purification, isoform characterization, and quantitation of human apolipoprotein A-IV |
| Q71371355 | Quantitation of apolipoprotein E |
| Q34172616 | Recent progress in histochemistry and cell biology |
| Q33597635 | Receptor-mediated mechanisms of lipoprotein remnant catabolism |
| Q45083057 | Role of apolipoprotein E in renal damage protection |
| Q35200206 | Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation |
| Q39558258 | Severe xanthomatosis associated with familial apolipoprotein E deficiency |
| Q89784271 | Systemic lupus erythematosus aggravates atherosclerosis by promoting IgG deposition and inflammatory cell imbalance |
| Q34289373 | The Fat‐Fed Apolipoprotein E Knockout Mouse Brachiocephalic Artery in the Study of Atherosclerotic Plaque Rupture |
| Q64058549 | The Opposite Effect of c-Jun Transcription Factor on Apolipoprotein E Gene Regulation in Hepatocytes and Macrophages |
| Q92252120 | The impact of APOE genotype on survival: Results of 38,537 participants from six population-based cohorts (E2-CHARGE) |
| Q33213990 | The key role of apolipoprotein E in atherosclerosis |
| Q38618173 | The role of apoproteins in disorders of lipoprotein metabolism |
| Q41161234 | The underlying molecular mechanism of apolipoprotein E polymorphism: relationships to lipid disorders, cardiovascular disease, and Alzheimer's disease. |
| Q72386082 | The uptake of chylomicron remnants and very low density lipoprotein remnants by the perfused rat liver |
| Q41755840 | Transgenic mouse models to study the role of APOE in hyperlipidemia and atherosclerosis |
| Q41662550 | Variable phenotypic expression of nonsense mutation p.Thr5* in the APOE gene |
Search more.